Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Organic Process R&DOrganic Process R&D
Not Confirmed
Not Confirmed
10-12 March, 2025
European Pharma Congre...European Pharma Congress
Not Confirmed
Not Confirmed
10-11 March, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Organic Process R&DOrganic Process R&D
Industry Trade Show
Not Confirmed
10-12 March, 2025
European Pharma Congre...European Pharma Congress
Industry Trade Show
Not Confirmed
10-11 March, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals
07 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/07/3038987/0/en/Novartis-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-2025-Annual-General-Meeting.html
28 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/28/3034762/0/en/Novartis-data-presentations-at-AAAAI-and-AAD-underscore-commitment-to-advancing-treatment-of-hidradenitis-suppurativa-HS-and-chronic-spontaneous-urticaria-CSU.html
28 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/28/3034670/0/en/Novartis-oral-Fabhalta-iptacopan-receives-positive-CHMP-opinion-for-the-treatment-of-adults-living-with-C3-glomerulopathy-C3G.html
19 Feb 2025
// BIOSPECTRUM
https://www.biospectrumasia.com/news/47/25603/hmri-partners-with-novartis-australia-to-supercharge-heart-health.html
12 Feb 2025
// REUTERS
https://www.reuters.com/markets/deals/novartis-agrees-acquire-anthos-up-31-bln-2025-02-11/
01 Feb 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/novartis-gives-anti-cd40-antibody-treat-sjogrens-due-benefitrisk-profile
Details:
Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.
Lead Product(s): Iptacopan Hydrochloride
Therapeutic Area: Nephrology Brand Name: Fabhalta
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2025
Lead Product(s) : Iptacopan Hydrochloride
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis oral Fabhalta® (iptacopan) Receives Positive CHMP Opinion
Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.
Product Name : Fabhalta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2025
Details:
Systane Pro PF (propylene glycol) is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes.
Lead Product(s): Mono Propylene Glycol
Therapeutic Area: Ophthalmology Brand Name: Systane Pro PF
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2025
Lead Product(s) : Mono Propylene Glycol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alcon Launches New Systane PRO Preservative-Free in The US
Details : Systane Pro PF (propylene glycol) is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes.
Product Name : Systane Pro PF
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2025
Details:
IsoLabs and Novartis will expand the scope of the initial collaboration, adding up to three additional research programs to discover small molecule therapeutics against three undisclosed targets.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Other Small Molecule
Recipient: Isomorphic Labs
Deal Size: $1,237.5 million Upfront Cash: $37.5 million
Deal Type: Collaboration February 18, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Recipient : Isomorphic Labs
Deal Size : $1,237.5 million
Deal Type : Collaboration
Isomorphic Labs Announces Novartis Collaboration Expansion
Details : IsoLabs and Novartis will expand the scope of the initial collaboration, adding up to three additional research programs to discover small molecule therapeutics against three undisclosed targets.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $37.5 million
February 18, 2025
Details:
Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.
Lead Product(s): Abelacimab
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868
Study Phase: Phase IIIProduct Type: Antibody
Recipient: Anthos Therapeutics
Deal Size: $3,075.0 million Upfront Cash: $925.0 million
Deal Type: Acquisition February 11, 2025
Lead Product(s) : Abelacimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Anthos Therapeutics
Deal Size : $3,075.0 million
Deal Type : Acquisition
Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront
Details : Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.
Product Name : MAA868
Product Type : Antibody
Upfront Cash : $925.0 million
February 11, 2025
Details:
The collaboration between Novartis and Light Horse offers a remarkable opportunity to utilize a genetic screening platform and proprietary chemical libraries to develop innovative cancer treatments.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Other Small Molecule
Recipient: Light Horse Therapeutics
Deal Size: $1,025.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration January 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Light Horse Therapeutics
Deal Size : $1,025.0 million
Deal Type : Collaboration
Light Horse Therapeutics Enters Into Strategic Collaboration with Novartis
Details : The collaboration between Novartis and Light Horse offers a remarkable opportunity to utilize a genetic screening platform and proprietary chemical libraries to develop innovative cancer treatments.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
January 09, 2025
Details:
Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.
Lead Product(s): Onasemnogene Abeparvovec
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2024
Lead Product(s) : Onasemnogene Abeparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Phase III Study of Onasemnogene Abeparvovec Meets Primary Endpoint in SMA
Details : Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 30, 2024
Details:
The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms related to age-related diseases and conditions.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: 20
Study Phase: Discovery PlatformProduct Type: Undisclosed
Recipient: BioAge Labs
Deal Size: $550.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration December 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery Platform
Recipient : BioAge Labs
Deal Size : $550.0 million
Deal Type : Collaboration
BioAge Partners with Novartis On Age-Related Disease Therapy Target Discovery
Details : The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms related to age-related diseases and conditions.
Product Name : 20
Product Type : Undisclosed
Upfront Cash : $20.0 million
December 18, 2024
Details:
UCB0599 (minzasolmin), an investigational, oral small molecule, alpha-synuclein misfolding inhibitor, being developed in partnership with Novartis for Parkinson’s disease failed to meet endpoints.
Lead Product(s): Minzasolmin
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Recipient: UCB Pharma S.A
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2024
Lead Product(s) : Minzasolmin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : UCB Pharma S.A
Deal Size : Not Applicable
Deal Type : Not Applicable
Minzasolmin Proof-of-Concept Study Shapes UCB Parkinson’s Research Program Next Steps
Details : UCB0599 (minzasolmin), an investigational, oral small molecule, alpha-synuclein misfolding inhibitor, being developed in partnership with Novartis for Parkinson’s disease failed to meet endpoints.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 16, 2024
Details:
Under the licensing agreement, Novartis will gain exclusive global rights to develop, manufacture, and commercialize MRT-6160, currently under study for immune-mediated conditions.
Lead Product(s): MRT-6160
Therapeutic Area: Immunology Brand Name: MRT-6160
Study Phase: Phase IProduct Type: Small molecule
Recipient: Monte Rosa Therapeutics
Deal Size: $2,250.0 million Upfront Cash: $150.0 million
Deal Type: Licensing Agreement December 11, 2024
Lead Product(s) : MRT-6160
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Monte Rosa Therapeutics
Deal Size : $2,250.0 million
Deal Type : Licensing Agreement
Monte Rosa, Novartis Close Deal on VAV1 Molecular Glue for T And B Cell Modulation
Details : Under the licensing agreement, Novartis will gain exclusive global rights to develop, manufacture, and commercialize MRT-6160, currently under study for immune-mediated conditions.
Product Name : MRT-6160
Product Type : Small molecule
Upfront Cash : $150.0 million
December 11, 2024
Details:
Kisqali (ribociclib) is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Lead Product(s): Ribociclib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2024
Lead Product(s) : Ribociclib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novartis Kisqali® NATALEE Data Show Durable Reduction in Recurrence in Early Breast Cancer
Details : Kisqali (ribociclib) is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 10, 2024
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Film-Coated Tablets
Dosage Strength : 180mg
Packaging :
Brand Name : Myfortic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Film-Coated Tablets
Dosage Strength : 360mg
Packaging :
Brand Name : Myfortic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Inf Conc
Dosage Strength : 4mg/5ml
Packaging :
Brand Name : Zometa
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Film-Coated Tablets
Dosage Strength : 150mg
Packaging :
Brand Name : Piqray
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Film-Coated Tablets
Dosage Strength : 150mg
Packaging :
Brand Name : Piqray
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Filmtabl
Dosage Strength : 200mg
Packaging :
Brand Name : Piqray
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Filmtabl
Dosage Strength : 200mg+50mg
Packaging :
Brand Name : Piqray
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Filmtabl
Dosage Strength : 200mg+50mg
Packaging :
Brand Name : Piqray
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Kaps
Dosage Strength : 100mg
Packaging :
Brand Name : Symmetrel
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Novartis Pharmaceuticals Corporation
Dosage Form : Filmtabl
Dosage Strength : 10mg/160mg
Packaging :
Brand Name : Exforge
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Australia
Dosage Form : Eye Drop; Eye Drop
Dosage Strength : 1MG/1ML; 3MG/1ML
Packaging : 1
Brand Name : Tears Naturale
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : Eye Drop; Eye Drop
Dosage Strength : 1MG/1ML; 3MG/1ML
Packaging : 1
Brand Name : Poly-Tears
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : Eye Drop; Eye Drop
Dosage Strength : 1MG/1ML; 3MG/1ML
Packaging : 1
Brand Name : Tears Naturale
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : Eye Drop; Eye Drop
Dosage Strength : 1MG/1ML; 3MG/1ML
Packaging : 1
Brand Name : Poly-Tears
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : Eye Drop; Eye Drop
Dosage Strength : 1MG/1ML; 3MG/1ML
Packaging : 1
Brand Name : Tears Naturale
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form : Eye Drop; Eye Drop
Dosage Strength : 1MG/1ML; 3MG/1ML
Packaging : 1
Brand Name : Poly-Tears
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 1
Brand Name : Genteal
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 1
Brand Name : In a Wink Moisturising
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 1
Brand Name : Genteal
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Dosage Form :
Dosage Strength :
Packaging : 1
Brand Name : Genteal
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : U.S.A
Dosage Form : Solution for injection
Brand Name : Fluorescite
Dosage Strength : 10%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : U.S.A
Regulatory Info :
Registration Country :
Novartis Pharmaceuticals Corporation
Dosage Form : Tablet
Brand Name : Isturisa
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Regulatory Info :
Registration Country :
Novartis Pharmaceuticals Corporation
Dosage Form : Tablet
Brand Name : Isturisa
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Regulatory Info :
Registration Country :
Novartis Pharmaceuticals Corporation
Dosage Form : Tablet
Brand Name : Isturisa
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country :
Excipients
Inspections and registrations
ABOUT THIS PAGE
Novartis Pharmaceuticals Corporation is a supplier offers 41 products (APIs, Excipients or Intermediates).
Find a price of Pentetreotide bulk with DMF, JDMF offered by Novartis Pharmaceuticals Corporation
Find a price of Valsartan bulk with DMF, CEP offered by Novartis Pharmaceuticals Corporation
Find a price of Amlodipine Besylate bulk with CEP offered by Novartis Pharmaceuticals Corporation
Find a price of Baclofen bulk with DMF offered by Novartis Pharmaceuticals Corporation
Find a price of Cefepime Hydrochloride bulk with JDMF offered by Novartis Pharmaceuticals Corporation
Find a price of Ceftriaxone bulk with JDMF offered by Novartis Pharmaceuticals Corporation
Find a price of Cyclosporine bulk with JDMF offered by Novartis Pharmaceuticals Corporation
Find a price of Fluvastatin bulk with DMF offered by Novartis Pharmaceuticals Corporation
Find a price of Glycolide - lactide copolymer bulk with DMF offered by Novartis Pharmaceuticals Corporation
Find a price of Letrozole bulk with CEP offered by Novartis Pharmaceuticals Corporation
Find a price of NAFTIFINE HCL bulk with DMF offered by Novartis Pharmaceuticals Corporation
Find a price of Penicillin G Benzathine bulk with JDMF offered by Novartis Pharmaceuticals Corporation
Find a price of Terbinafine bulk with DMF offered by Novartis Pharmaceuticals Corporation
Find a price of Topotecan Hydrochloride bulk with DMF offered by Novartis Pharmaceuticals Corporation
Find a price of Benzonatate bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Bisoctrizole bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Chlorthalidone bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Clofazimine bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Clomipramine Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Edotreotide bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Eudragit Rs bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Methylphenidate Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Naphazoline Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Pyrilamine bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Pyrilamine Maleate bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Rifampicin bulk offered by Novartis Pharmaceuticals Corporation
Find a price of Thurfyl Nicotinate bulk offered by Novartis Pharmaceuticals Corporation
Find a price of STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by Novartis Pharmaceuticals Corporation
Find a price of CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by Novartis Pharmaceuticals Corporation
Find a price of PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by Novartis Pharmaceuticals Corporation
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by Novartis Pharmaceuticals Corporation
Find a price of TESSALON DRUG SUBSTANCE bulk offered by Novartis Pharmaceuticals Corporation
Find a price of CGP 17,582B bulk offered by Novartis Pharmaceuticals Corporation
Find a price of PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by Novartis Pharmaceuticals Corporation
Find a price of 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by Novartis Pharmaceuticals Corporation
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by Novartis Pharmaceuticals Corporation
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by Novartis Pharmaceuticals Corporation
Find a price of ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by Novartis Pharmaceuticals Corporation
Find a price of PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by Novartis Pharmaceuticals Corporation
Find a price of TINUVIN 326 bulk offered by Novartis Pharmaceuticals Corporation
Find a price of FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by Novartis Pharmaceuticals Corporation